Yu-Yun Shao1,2,3, Ann-Lii Cheng1,2,3,4, Chih-Hung Hsu1,2,3. 1. Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. 2. Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. 3. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. 4. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Abstract
BACKGROUND: Many systemic therapies for advanced hepatocellular carcinoma (HCC) may cause hypothyroidism; however, in these patients, hypothyroidism prevalence before therapy and its prognostic impact remain unclear. MATERIALS AND METHODS: We previously established a prospective cohort of patients who received sorafenib as first-line therapy for advanced HCC. No patients had been clinically diagnosed with hypothyroidism before or during sorafenib treatment. We retrospectively determined the levels of thyrotropin and free thyroxine before initiation of systemic therapy. Hypothyroidism was defined as thyrotropin level higher than the upper limit of the normal range. Among patients with hypothyroidism, free thyroxine level less than the lower normal range was defined as overt hypothyroidism, and free thyroxine level within the normal range was defined as subclinical hypothyroidism. RESULTS: In total, 79 patients were enrolled; of them, 16 (20%) had hypothyroidism (overt hypothyroidism, 10; subclinical hypothyroidism, 6). Patients with hypothyroidism, compared with those without hypothyroidism, were more likely to be older than 65 years (56% vs. 29%, p = .037), have a serum α-fetoprotein level of >400 ng/mL (81% vs. 52%, p = .037), and have a significantly poorer overall survival (OS; median, 5.5 vs. 11.6 months, p = .043). After adjusting for other potential prognostic factors, hypothyroidism remained an independent predictor for poorer OS (hazard ratio, 2.53, p = .018). Patients with overt hypothyroidism and subclinical hypothyroidism exhibited similarly poor OS (p = .768). CONCLUSION: Underdiagnosis of hypothyroidism in patients with advanced HCC was common. Hypothyroidism, whether overt or subclinical, is associated with poor prognosis of advanced HCC. IMPLICATIONS FOR PRACTICE: The results of this study showed the underdiagnosis of hypothyroidism in patients with advanced hepatocellular carcinoma (HCC) and its influence on prognosis. These findings implied the importance of thyroid function check before initiation of systemic therapy for patients with advanced HCC.
BACKGROUND: Many systemic therapies for advanced hepatocellular carcinoma (HCC) may cause hypothyroidism; however, in these patients, hypothyroidism prevalence before therapy and its prognostic impact remain unclear. MATERIALS AND METHODS: We previously established a prospective cohort of patients who received sorafenib as first-line therapy for advanced HCC. No patients had been clinically diagnosed with hypothyroidism before or during sorafenib treatment. We retrospectively determined the levels of thyrotropin and free thyroxine before initiation of systemic therapy. Hypothyroidism was defined as thyrotropin level higher than the upper limit of the normal range. Among patients with hypothyroidism, free thyroxine level less than the lower normal range was defined as overt hypothyroidism, and free thyroxine level within the normal range was defined as subclinical hypothyroidism. RESULTS: In total, 79 patients were enrolled; of them, 16 (20%) had hypothyroidism (overt hypothyroidism, 10; subclinical hypothyroidism, 6). Patients with hypothyroidism, compared with those without hypothyroidism, were more likely to be older than 65 years (56% vs. 29%, p = .037), have a serum α-fetoprotein level of >400 ng/mL (81% vs. 52%, p = .037), and have a significantly poorer overall survival (OS; median, 5.5 vs. 11.6 months, p = .043). After adjusting for other potential prognostic factors, hypothyroidism remained an independent predictor for poorer OS (hazard ratio, 2.53, p = .018). Patients with overt hypothyroidism and subclinical hypothyroidism exhibited similarly poor OS (p = .768). CONCLUSION: Underdiagnosis of hypothyroidism in patients with advanced HCC was common. Hypothyroidism, whether overt or subclinical, is associated with poor prognosis of advanced HCC. IMPLICATIONS FOR PRACTICE: The results of this study showed the underdiagnosis of hypothyroidism in patients with advanced hepatocellular carcinoma (HCC) and its influence on prognosis. These findings implied the importance of thyroid function check before initiation of systemic therapy for patients with advanced HCC.
Authors: T Okanoue; S Sakamoto; Y Itoh; M Minami; K Yasui; M Sakamoto; K Nishioji; T Katagishi; Y Nakagawa; H Tada; Y Sawa; M Mizuno; K Kagawa; K Kashima Journal: J Hepatol Date: 1996-09 Impact factor: 25.083
Authors: P Marcellin; M Pouteau; P Renard; J M Grynblat; N Colas Linhart; P Bardet; B Bok; J P Benhamou Journal: Gut Date: 1992-06 Impact factor: 23.059
Authors: Marta Anna Kowalik; Elisabetta Puliga; Lavinia Cabras; Pia Sulas; Annalisa Petrelli; Andrea Perra; Giovanna Maria Ledda-Columbano; Andrea Morandi; Simone Merlin; Claudia Orrù; Carlos Sanchez-Martin; Francesca Fornari; Laura Gramantieri; Matteo Parri; Andrea Rasola; Sara Erika Bellomo; Carlos Sebastian; Antonia Follenzi; Silvia Giordano; Amedeo Columbano Journal: J Hepatol Date: 2020-01-15 Impact factor: 25.083
Authors: G E Bekkering; T Agoritsas; L Lytvyn; A F Heen; M Feller; E Moutzouri; H Abdulazeem; B Aertgeerts; D Beecher; J P Brito; P D Farhoumand; N Singh Ospina; N Rodondi; M van Driel; E Wallace; M Snel; P M Okwen; R Siemieniuk; P O Vandvik; T Kuijpers; M Vermandere Journal: BMJ Date: 2019-05-14